Skip to Content

Fidelity Advisor® Biotechnology C FBTCX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 18.31  /  1.67 %
  • Total Assets 1.4 Bil
  • Adj. Expense Ratio
    1.760%
  • Expense Ratio 1.760%
  • Distribution Fee Level Low
  • Share Class Type Level Load
  • Category Health
  • Investment Style Mid Value
  • Min. Initial Investment
  • Status Open
  • TTM Yield
  • Turnover 78%

Morningstar’s Analysis FBTCX

Will FBTCX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Fidelity Advisor ® Biotechnology C earns a Morningstar Medalist Rating of Neutral with strength in areas such as People offset by weaker spots such as Process.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the most expensive quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBTCX

  • Current Portfolio Date
  • Equity Holdings 79
  • Bond Holdings 0
  • Other Holdings 15
  • % Assets in Top 10 Holdings 63.6
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector
24.01
327,040,646
Healthcare
10.69
145,683,452
Healthcare
9.19
125,251,665
Healthcare
3.67
50,066,060
Healthcare
3.32
45,202,024
Healthcare
3.06
41,650,859
Healthcare
2.83
38,555,075
Healthcare
2.42
33,016,604
Healthcare
2.30
31,312,176
Healthcare
2.15
29,302,305
Healthcare